DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
I'm - 1 Becton - 1 Becton Dickinson - 1 Robert F - 1 Kennedy Jr - 1 Scott Chronert - 1 Keith Horowitz - 1 Horowitz - 1
Top related locs:
Columbia Stifel Williston Gilead
Top related orgs:
Boeing - 2 Biosciences - 2 HHS - 1 IDEAYA Biosciences - 1 AstraZeneca - 1 Citi - 1 Nasdaq - 1 Dow Jones - 1

Search resuls for: "IDEAYA Biosciences"


4 mentions found


☆ Cramer's Lighting Round: 'I'm not going to recommend' Altria
  + stars: | 2024-11-14 | by ( Julie Coleman | ) www.cnbc.com   time to read: +1 min
Stock Chart Icon Stock chart icon Altria's year-to-date stock performance. Stock Chart Icon Stock chart icon Boeing's year-to-date stock performance. Stock Chart Icon Stock chart icon Becton Dickinson's year-to-date stock performance. Stock Chart Icon Stock chart icon IDEAYA Biosciences' year-to-date stock performance. Stock Chart Icon Stock chart icon AstraZeneca's year-to-date stock performance.
Persons: I'm, Becton, Becton Dickinson, Robert F, Kennedy Jr Organizations: Boeing, HHS, Biosciences, IDEAYA Biosciences, AstraZeneca
☆ Citi gives its top picks for clients heading into the fourth quarter
  + stars: | 2024-10-03 | by ( Sean Conlon | ) www.cnbc.com   time to read: +3 min
As the fourth quarter gets underway, there are some stocks that may be poised to outperform over the next several months, according to Citi. "Now, broadening is apparent, with Value leading while Growth has not yet achieved July levels," Scott Chronert said in a Friday note to clients. Citi views newly added Ally Financial as "one of the best-positioned liability sensitive names," seeing the potential for total book value growth of 25% by the fourth quarter of next year. "While mistakes were clearly made with the '22 auto vintage, the short duration of this asset class implies ALLY will not be stuck with the problem beyond 2025," analyst Keith Horowitz wrote. Meanwhile, Citi has a buy rating on the stock, and its price target of $50 implies nearly 45% upside from Wednesday's close.
Persons: Scott Chronert, Keith Horowitz, Horowitz, Ally, Stephen Trent, Filippo Falorni Organizations: Citi, Nasdaq, Dow Jones, North America, Biosciences, Alnylam Pharmaceuticals, Ally, United Airlines, United
☆ Stocks making the biggest moves midday: Paramount Global, Morphic Holding, Ideaya Biosciences and more
  + stars: | 2024-07-08 | by ( Sean Conlon | ) www.cnbc.com   time to read: +3 min
Skydance and its financial backers will invest more than $8 billion into Paramount and to acquire National Amusements, Paramount's controlling shareholder. Morphic Holding – Shares rallied 75% on news that Eli Lilly will acquire the biopharmaceutical company in a $3.2 billion deal . The deal will give Eli Lilly access to Morphic's portfolio of treatments in development, such as those for ulcerative colitis and Crohn's disease. Shares of Eli Lilly advanced 1.3% on the news. Boeing – Shares fell slightly after the airplane maker agreed to plead guilty to criminal fraud related to the fatal 737 Max crashes, sparing Boeing from a trial.
Persons: Eli Lilly, BofA, Corning, Guggenheim, Max, Grayson, Raymond James, Samantha Subin, Pia Singh, Hakyung Kim, Sarah Min, Michelle Fox Organizations: Paramount Global, Skydance Media, Skydance, Paramount, National, Morphic, Ideaya Biosciences, Bank of America, Boeing –, Boeing, ., CNBC, Devon Energy, Gilead Sciences Locations: Columbia, Stifel, Williston, Gilead
☆ Stocks making the biggest moves midday: Tesla, Southwest, Apple, AMC and more
  + stars: | 2022-12-28 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Shares of AMC Entertainment more than quadrupled today as investors continue their buying spree on heavily shorted stocks. Baird also trimmed its price target on shares to $252 from $316 a share. AMC Entertainment – AMC Entertainment shares dipped about 3% a day after CEO Adam Aron tweeted that he asked the company's board to freeze his 2023 pay and urged other executives to forgo salary bumps. Maxeon — Shares slid 8% after the solar company announced Bill Mulligan would be the new CEO. The firm gave the stock a price target of $29, which presents an upside of 75.4% over where it closed Tuesday.
0 next >>
Total: 4